Use of Staphylococcus aureus Phage Lysate Staphage Lysate (SPL)® for the Control of Recurrent Pyoderma Eczema in Dogs with Atopic Dermatitis

Suzana Evelyn Bahr Solomon, Marconi Rodrigues de Farias, Claudia Turra Pimpão

Abstract


Background: Recurrent staphylococcal infections are frequent in dogs with atopic dermatitis (AD). Many factors seem to contribute to making bacterial pyoderma refractory to treatment. Short-term systemic antibiotic therapy is effective for the treatment of acute symptoms, and may, along with pulsatile therapy, contribute to the long-term control of the disease. However, microbial resistance has become a growing and alarming problem. The aim of this study was to evaluate whether the use of Staphylococcus aureus Phage Lysate Staphage Lysate (SPL)®, can minimize the symptoms of recurrent pyoderma and increase the interval between acute atopic manifestations in dogs.

Materials, Methods & Results: Thirteen dogs with a history of Canine Atopic Dematitis (CAD) and recurrent bacterial pyoderma received SPL at increasing intervals for 23 weeks. The contents of an intact pustule of each dog was collected and submitted to microbiological analysis. Systemic antibiotic therapy was established for the first 4-6 weeks of SPL protocol, based on the antibiotic sensitivity tests. The animals included in the study underwent a therapeutic protocol receiving shots of 0.5 mL of SPL subcutaneously (SC) twice a week for the first 12 weeks; 1.0 mL of SPL (SC) once a week for four weeks; 1.0 mL of SPL (SC) once every 15 days; 1.0 mL of SPL (SC) after a three-week interval from the last dose on week 20, until final observation at week 26, with no application. The animals underwent clinical examination every week and the evaluation of pruritus was used according Rybnicek et al. During the therapeutic protocol with SPL, a significant decline in the pruritus was observed in the treated dogs (P < 0.05). In week 1, the mean pruritus index was 7.33 on the Rybnicek scale; in weeks 12 and 23, the mean indices were 2.41 and 1.91. An effectiveness of 83.33% for the control of pruritus along with regression of the lesions was observed.

Discussion: Before treatment, the selected animals presented worsening of the pruritus during the pyoderma eczema episodes (pruritic), resulting in the emergence of a vicious cycle where the pruritus induced the appearance of new lesions, requiring the use of antibiotics for a long period. During the therapeutic protocol with SPL, a significant decline in the pruritus was observed in the treated dogs. The control of pruritus associated with pyoderma eczema of the dogs in this study before the vaccination protocol with SPL was satisfactory when they were subjected to antibiotic therapy; however, after suspending therapy, the bacterial infections recurred, on average, after 2-4 weeks. On the other hand, with the use of SPL, the animals were recurrence-free until the end of the experimental protocol. This was attributed to the antibiotic therapy administered at the beginning of the protocol, as this led to a regression of the bacterial pyoderma and involution of the lesions. However, after suspending antibiotics, it was observed that, by the end of the study, 83.33% of the dogs still had a low level of pruritus, few or no lesions, which were considered acceptable to most owners. At this moment none of these patients needed to be subjected to antibiotic treatment. The sums of the scores for the dogs on weeks 1, 12, and 23 were 53.33, 4.41, and 3.5, respectively, indicating significant improvements of the lesions, showing that the proposed protocol with SPL was able to prevent new episodes of pyoderma.


Keywords


atopic dermatitis; keratinocytes; pyoderma; bacterin.

Full Text:

PDF

References


Bannoehr J., Ben Zakour N.L., Waller A.S., Guardabassi L., Thoday K.L., van den Broek A.H. & Fitzgerald J.R. 2007. Population genetic structure of the Staphylococcus intermedius group: insights into agr diversification and the emergence of methicillin-resistant strains. Journal of Bacteriology. 189(23): 8685-8692.

Bannoehr J., Franco A., Iurescia M., Battisti A. & Fitzgerald J.R. 2009. Molecular Identification of Staphylococcus pseudintermedius. Journal of Clinical Microbiology. 47(2): 469-471.

Carlotti D.N., Jasmin P., Gardey L. & Sanquer A. 2004. Evaluation of cephalexin intermittent therapy (weekend therapy) in the control of recurrent idiopathic pyoderma in dogs: a randomized, double-blinded, placebo-controlled study. Veterinary Dermatology. 15(1): 8-9.

Curtis C.F., Lamport A.I. & Lloyd D.H. 2006. Masked, controlled study to investigate the efficacy of a Staphylococcus

intermedius autogenous bacterin for the contol of canine idiopathic recurrent superficial pyoderma. Veterinary Dermatology. 17(3): 163-168.

Deboer D.J. & Marsella R. 2001. The ACVD task force on canine atopic dermatitis (XII): the relationship of cutaneus infections to the patogenesis and clinical course of canine atopic dermatitis. Veterinary Immunology and Immunopathology. 81(3-4): 239-249.

Deboer D.J., Moriello K.A., Thomas C.B. & Schultz K.T. 1990. Evaluation of a commercial staphylococcal bacterin for management of idiopathic recurrent superficial pyoderma in dogs. American Journal of Veterinary Research. 51(4): 636-639.

Fazakerley J., Nuttall T., Sales D., Schmidt V., Carter S.D., Hart C.A. & Mcewan N.A. 2009. Staphylococcal colonization of mucosal and lesional skin sites in atopic and healthy dogs. Veterinary Dermatology. 20(3): 179-184.

Fazakerley J., Williams N.J., Carter S.D., McEwan N.A. & Nuttall T.J. 2010. Heterogeneity of Staphylococcus pseudintermedius isolates from atopic and healthy dogs. Veterinary Dermatology. 21(6): 578-585.

Fitzgerald J.R. 2009. The Staphylococcus intermedius group of Bacterial pathogens: species re-classification, pathogenesis and the emergence of meticillin resistance. Veterinary Dermatology. 20(5-6): 490-495.

Foster A.P. 2004. Immunomodulation and immunodeficiency. Veterinary Dermatology. 15(2): 115-126.

Fulham K.S., Lemarie S.L., Hosgood G. & Dick H.L.N. 2010. In vitro susceptibility testing of meticillin-resistant and meticillin-susceptible staphylococci to mupirocin and novobiocin. Veterinary Dermatology. 22(1): 88-94.

Krishnan G. & Ganfield D.J. 1994. Cytokines produced by Staphage Lysate. In: 12th European Immunology Meeting - Abstracts (Barcelona, Spain). p.395.

Lloyd D.H. 2009. Microbial diseases secondary to allergic skin disease - clinical significance and control. European Journal of Companion Animal Practice. 19(3): 254-260.

Loeffler A., Linek M., Moodley A., Guardabassi L., Sung J.M., Winkler M., Weiss R. & Lloyd D.H. 2007. First report of multiresistant, mecA-positive Staphylococcus intermedius in Europe: 12 cases from a veterinary dermatology referral clinic in Germany. Veterinary Dermatology. 18(6): 412-421.

Marsella R. & Samuelson D. 2009. Unravelling the skin barrier: a new paradigm for atopic dermatitis and house dust mites. Veterinary Dermatology. 20(5-6): 533-540.

Mcewan N.A. 2000. Adherence by Staphylococcus intermedius to canine keratinocytes in atopic dermatitis. Research in Veterinary Science. 68(3): 279-283.

McEwan N.A., Mellor D. & Kalna G. 2006. Adherence by Staphylococcus intermedius to canine corneocytes: a preliminary study comparing noninflamed and inflamed atopic canine skin. Veterinary Dermatology. 17(2): 151-154.

Morales C.A., Schultz K.T. & DeBoer D.J. 1994. Anti-staphylococcal antibodies in dogs with recurrent staphylococcal pyoderma. Veterinary Immunology Immunopathology. 42(2): 137-147.

Morris D.O., Boston R.C., O’Shea K. & Rankin S.C. 2010. The prevalence of carriage of meticillin-resistant staphylococci by veterinary dermatology practice staff and their respective pets. Veterinary Dermatology. 21(4): 400-407.

Morris D.O., Rook K.A., Shofer F.S. & Rankin S.C. 2006. Screening of Staphylococcus aureus, Staphylococcus intermedius, and Staphylococcus schleiferi isolates obtained from small companion animals for antimicrobial resistance: a retrospective review of 749 isolates (2003-04). Veterinary Dermatology. 17(5): 332-337.

Nograles K.E., Suárez-Fariñas M., Shemer A., Fuentes-Duculan J., Chiricozzi A., Cardinale I., Zaba L.C., Kikuchi T., Ramon M., Bergman R., Krueger J.G. & Guttman-Yassky E. 2010. Atopic dermatitis keratinocytes exhibit normal Th17 cytokine responses. The Journal of Allergy Clinical Immunology. 125(3): 744-746.

Olivry T., Deboer D.J., Favrot C., Jackson H.A., Mueller R.S., Nuttall T. & Prélaud P. 2010. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Veterinary Dermatology. 21(3): 233-248.

Penna B., Varges R., Medeiros L., Martins G.M., Martins R.R. & Lilenbaum W. 2009. In Vitro Antimicrobial Susceptibility of Staphylococci isolated from Canine Pyoderma in Rio de Janeiro, Brazil. Brazilian Journal of Microbiology. 40(3): 490-494.

Pianta C., Oliveira S.C., Fallavena L.C.B., Esmeraldino A.T. & Silva V.B. 2006. Pioderma estafilocócico canino: identificação das espécies e sensibilidade aos antimicrobianos. Revista de Ciências Agroveterinárias. 5(1): 60-63.

Prescott J.F., Hanna W.J., Reid-Smith R. & Drost K. 2002. Antimicrobial drug use and resistance in dogs. The Canadian Veterinary Journal. 43(2): 107-116.

Roosje P. 2005. Canine atopic dermatitis: new concepts. European Journal of Companion Animal Practice. 15(2): 189-195.

Rybnicek, J., Lau-Gillard P.J., Harvey R. & Hill P.B. 2009. Further validation of a pruritus severity scale for use in dogs. Veterinary Dermatology. 20(2): 115-122.

Schauber J. & Gallo R.L. 2008. Antimicrobial peptides and the skin immune defense system. Journal of Allergy and Clinical Immunology. 122(2): 261-266.

Simou C., Thoday K.L., Forsythe P.J. & Hill P.B. 2005. Adherence of Staphylococcus intermedius to corneocytes of healthy and atopic dogs: effect of pyoderma, pruritus score, treatment and gender. Veterinary Dermatology. 16(6): 385-391.




DOI: https://doi.org/10.22456/1679-9216.81103

Copyright (c) 2018 Suzana Evelyn Bahr Solomon, Marconi Rodrigues de Farias, Claudia Turra Pimpão

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.